MICHAEL L CAMILLERI

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Charlton 8 110, 200 First St SW, Rochester, MN 55905, USA
    IDrugs 13:921-8. 2010
  2. ncbi Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy
    Michael Camilleri
    Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Gastroenterol 40:264-9. 2006
  3. pmc RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R and
    Am J Physiol Gastrointest Liver Physiol 306:G1089-98. 2014
  4. doi Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies
    M Camilleri
    Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 32:1113-23. 2010
  5. pmc Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 23:935-e398. 2011
  6. ncbi Pathophysiology as a basis for understanding symptom complexes and therapeutic targets
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 16:135-42. 2004
  7. ncbi Chronic diarrhea: a review on pathophysiology and management for the clinical gastroenterologist
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 2:198-206. 2004
  8. doi Current medical treatments of dyspepsia and irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic College of Medicine, Charlton 8 110, 200 First Street Southwest, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 39:481-93. 2010
  9. doi Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy
    Michael Camilleri
    Department of Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Gastroenterol 42:S123-5. 2008
  10. ncbi Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 296:G510-6. 2009

Research Grants

Collaborators

Detail Information

Publications132 found, 100 shown here

  1. ncbi LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Charlton 8 110, 200 First St SW, Rochester, MN 55905, USA
    IDrugs 13:921-8. 2010
    ..LX-1031 was well tolerated in trials to date. In conclusion, LX-1031 appears promising for IBS-D. Optimal doses, efficacy in IBS clinical trials and safety need to be fully elucidated...
  2. ncbi Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy
    Michael Camilleri
    Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Gastroenterol 40:264-9. 2006
    ..Colonic transit was retarded in IBS patients treated with VSL#3 without induction of significant changes in bowel function. In summary, probiotics are promising therapies in IBS...
  3. pmc RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R and
    Am J Physiol Gastrointest Liver Physiol 306:G1089-98. 2014
    ..RNA-Seq and RT-PCR analysis of rectosigmoid mucosa in IBS-D show transcriptome changes that provide the rationale for validation studies to explore the role of mucosal factors in the pathobiology of IBS-D...
  4. doi Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies
    M Camilleri
    Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 32:1113-23. 2010
    ..Prucalopride is approved in Europe for symptomatic treatment of chronic constipation in women with inadequate relief from laxatives...
  5. pmc Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 23:935-e398. 2011
    ..Our aim was to preliminarily assess association between 30 susceptibility loci for CD, three genes associated with PI-IBS, and PARM1, with colonic transit in lower functional gastrointestinal disorders (FGID)...
  6. ncbi Pathophysiology as a basis for understanding symptom complexes and therapeutic targets
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 16:135-42. 2004
    ....
  7. ncbi Chronic diarrhea: a review on pathophysiology and management for the clinical gastroenterologist
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 2:198-206. 2004
  8. doi Current medical treatments of dyspepsia and irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic College of Medicine, Charlton 8 110, 200 First Street Southwest, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 39:481-93. 2010
    ..Novel approaches to treatment require approval, and promising agents are guanylate cyclase cagonists, atypical benzodiazepines, antibiotics, immune modulators, and probiotics...
  9. doi Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy
    Michael Camilleri
    Department of Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Gastroenterol 42:S123-5. 2008
    ..probiotics change bacterial flora? Do probiotics adhere to mucosa? What are the potential mechanisms of action of probiotics in IBS: immune function, motor, secretory, sensory, and fermentation? What is the efficacy of probiotics in IBS?..
  10. ncbi Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 296:G510-6. 2009
    ..Thus variation in mtDNA may be associated with satiation, gastric emptying, and possibly pain; further studies of mtDNA in appetite regulation and larger numbers of patients with FGIDs are warranted...
  11. ncbi GIH clinical research update: 2004-2005
    Michael Camilleri
    Clinical Gastroenterology and Hepatology Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 3:1161-6. 2005
    ..These areas of clinical research demonstrate the breadth of significant advances that will impact on the clinical practice of gastroenterology and hepatology...
  12. doi Lubiprostone for the treatment of opioid-induced bowel dysfunction
    Banny S Wong
    College of Medicine, Mayo Clinic, Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Rochester, MN 55905, USA
    Expert Opin Pharmacother 12:983-90. 2011
    ....
  13. ncbi New therapeutic approaches in irritable bowel syndrome
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER Program, Mayo Clinic, Rochester, MN, USA
    Eur Rev Med Pharmacol Sci 12:139-40. 2008
  14. ncbi GIH clinical research 2003-2004: the year in review
    Michael Camilleri
    May Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 2:1043-7. 2004
    ..Clinical research advances will impact the management of digestive diseases...
  15. ncbi Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 19:77-84. 2007
    ..The evidence reviewed suggests that further studies are needed to explore the principles to prove or disprove the association...
  16. ncbi New imaging in neurogastroenterology: an overview
    M Camilleri
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Neurogastroenterol Motil 18:805-12. 2006
    ....
  17. pmc Brain-gut axis: from basic understanding to treatment of IBS and related disorders
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Pediatr Gastroenterol Nutr 54:446-53. 2012
    ..The criteria are similar in children and adults. The focus of the present review is the bowel dysfunction associated with IBS...
  18. pmc Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 20:971-9. 2008
    ..The 1.0 mg dose was also efficacious in IBS-alternating. There were also weeks with significant reduction in bowel frequency and urgency. Asimadoline has been well tolerated in human trials to date...
  19. pmc Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit
    Michael Camilleri
    Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905
    Am J Physiol Gastrointest Liver Physiol 306:G13-26. 2014
    ..027) and rs1966265 with 24-h colonic transit (P = 0.066). Thus exome sequencing identified additional variants in KLB and FGFR4 associated with bile acids or colonic transit in IBS-D. ..
  20. pmc Genetics of human gastrointestinal sensation
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 25:458-66. 2013
    ..The objective was to review the genetics of human visceral pain with particular emphasis on pain associated with irritable bowel syndrome...
  21. pmc Is there a SERT-ain association with IBS?
    M Camilleri
    Center, Mayo Clinic, Charlton 8 110, 200 First St SW, Rochester, MN 55905, USA
    Gut 53:1396-9. 2004
  22. doi Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome
    Michael Camilleri
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 303:G120-8. 2012
    ....
  23. pmc Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation
    Banny S Wong
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic, Rochester, Minnesota, USA
    Clin Exp Gastroenterol 3:49-56. 2010
    ..Prucalopride is a well tolerated and efficacious prokinetic medication that should enhance the treatment of chronic constipation unresponsive to first-line treatments...
  24. pmc Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases
    Madhusudan Grover
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, 200 First St S W, Charlton 8 110, Rochester, MN 55905, USA
    J Gastroenterol 48:177-81. 2013
    ..Antidepressants appear to be more effective in the treatment of patients with anxiety or depression, but larger prospective trials assessing both clinical and pharmacodynamic effects on gut sensorimotor function are needed...
  25. pmc Guanylate cyclase C signaling: an intestinal secretory pathway where bugs, genes and new drugs intersect
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C, E, N, T, E, R, College of Medicine, Mayo Clinic, Charlton 8 110, 200 First Street SW, Rochester, MN 55905, USA
    Genome Med 4:50. 2012
    ..This newly identified gene in the etiology of a familial diarrhea provides a candidate target for the development not only of new treatments for diarrhea, but also of a new drug class to treat constipation...
  26. doi Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome
    Michael Camilleri
    Mayo Clinic, Clinical Enteric Neuroscience Translational and Epidemiological Research, Charlton 8 110, 200 First St S W, Rochester, 55905 MN, USA
    Expert Opin Pharmacother 14:1151-60. 2013
    ..The ultimate goal in this field is to identify the underlying cause of symptoms in order to individualize education of the patient, and to provide optimal treatment of this highly prevalent condition...
  27. pmc Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 304:G553-60. 2013
    ....
  28. pmc Clinical guideline: management of gastroparesis
    Michael Camilleri
    Department of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Gastroenterol 108:18-37; quiz 38. 2013
    ..Partial gastrectomy and pyloroplasty should be used rarely, only in carefully selected patients. Attention should be given to the development of new effective therapies for symptomatic control...
  29. pmc Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 24:1076-e562. 2012
    ..Our aim was to assess inter- and intra-subject coefficients of variation (COV) of scintigraphic GE measurements in healthy subjects, and associations of GE with gender and body mass index (BMI)...
  30. pmc Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics
    Andrea Shin
    1Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, MN, USA
    Diabetes Care 36:41-8. 2013
    ..To investigate the pharmacokinetics (PK), pharmacodynamics, and safety of single-dose RM-131 in type 2 diabetic patients with gastrointestinal cardinal symptoms (GCSI) and previously documented delayed gastric emptying (DGE)...
  31. doi Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 303:G775-85. 2012
    ....
  32. pmc What are the important subsets of gastroparesis?
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 24:597-603. 2012
    ....
  33. pmc Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 302:G1075-84. 2012
    ..No published genome-wide association studies in functional gastrointestinal or motility disorders have been published...
  34. doi Governance of clinical research
    Michael Camilleri
    Division of Gastroenterology and Hepatology and Office of Human Research Protection, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 107:336-8. 2012
    ....
  35. pmc The role of pharmacogenetics in nonmalignant gastrointestinal diseases
    Michael Camilleri
    College of Medicine, Mayo Clinic, Charlton 8 110, 200 First Street South West, Rochester, MN 55905, USA
    Nat Rev Gastroenterol Hepatol 9:173-84. 2012
    ..However, pharmacogenetics could have a beneficial role in enabling pharmacotherapy for nonmalignant gastrointestinal diseases to be targeted to the individual patient...
  36. pmc New treatment options for chronic constipation: mechanisms, efficacy and safety
    Michael Camilleri
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Can J Gastroenterol 25:29B-35B. 2011
    ..Nevertheless, the spectrum of mechanisms and demonstrated efficacy and safety augur well for satisfactory treatment outcomes...
  37. pmc Pharmacogenetics of low dose clonidine in irritable bowel syndrome
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 21:399-410. 2009
    ..alpha2A, GNbeta3 and SLC6A4 genotypes significantly modify responses to CLO on sensory and motor GI functions in health and IBS...
  38. pmc Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Neurogastroenterol Motil 23:995-9, e458. 2011
    ..Our aim was to assess the association of genetic variation in TGR5 and small bowel transit (SBT) and colonic transit...
  39. pmc Serotonin in the gastrointestinal tract
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Endocrinol Diabetes Obes 16:53-9. 2009
    ..To assess the role of serotonin and its control in the manifestations and treatment of lower functional gastrointestinal disorders...
  40. ncbi The stomach in diabetes: from villain to ally
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiologic Research CENTER, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 7:285-7. 2009
    ..The stomach is not always a villain, but is an ally in patients with type 2 diabetes...
  41. pmc Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 22:e15-26. 2010
    ..The 0-5 or 6 h 2-SE urine likely reflects both SI and colon permeability; the higher LMR in the 8-24 h urine relative to 0-2 h urine should be interpreted with caution and does not mean that colon is more permeable than SI...
  42. pmc Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 135:1877-91. 2008
    ..The hope of providing relief to patients should galvanize all parties to achieve these goals...
  43. pmc Enteroendocrine and neuronal mechanisms in pathophysiology of acute infectious diarrhea
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Charlton 8 110, 200 First St SW, Rochester, MN 55905, USA
    Dig Dis Sci 57:19-27. 2012
    ....
  44. pmc Behavioural and new pharmacological treatments for constipation: getting the balance right
    Michael Camilleri
    Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905, USA
    Gut 59:1288-96. 2010
    ....
  45. doi Drug development and IBS drugs: experience from the past, current challenges, and proposal for the future
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER Program, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Pharmacol 8:671-6. 2008
    ..These extra validation steps will undoubtedly result in delays in drug development. Providing relief to patients should galvanize all parties to achieve effective and fair strategies for regulatory approval...
  46. ncbi Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device
    M Camilleri
    The Mayo Clinic, Rochester, Minnesota, USA
    Surgery 143:723-31. 2008
    ..The aim is to assess the effects of vagal blocking on excess weight loss (EWL), safety, dietary intake, and vagal function...
  47. pmc Candidate genes and sensory functions in health and irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, Mayo Clinic, Charlton 8 110, 200 1st St SW, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 295:G219-25. 2008
    ....
  48. ncbi A placebo-controlled trial of prucalopride for severe chronic constipation
    Michael Camilleri
    College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 358:2344-54. 2008
    ..In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation...
  49. pmc Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 21:734-e43. 2009
    ..This assay has potential as a non-invasive test for BAM in IBS...
  50. pmc Peripheral mechanisms in the control of appetite and related experimental therapies in obesity
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States
    Regul Pept 156:24-7. 2009
    ..Novel therapies are being developed to mimic or enhance these feedback mechanisms and to control appetite as a means to treat obesity...
  51. pmc Actions and therapeutic pathways of ghrelin for gastrointestinal disorders
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Gastroenterol Hepatol 6:343-52. 2009
    ..The potential of this new class of therapeutic agents to influence appetite and glycemic control strongly indicates that they should be tested in clinical trials...
  52. pmc Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation
    M Camilleri
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Neurogastroenterol Motil 22:874-82, e233. 2010
    ..Colon transit (CT) measurements are used in the management of significant constipation. The radiopaque marker (ROM) method provides limited information...
  53. doi Validation of a bowel function diary for assessing opioid-induced constipation
    Michael Camilleri
    Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 106:497-506. 2011
    ..Validated tools to assess opioid-induced constipation (OIC) are needed. The aim of this study was to validate a Bowel Function Diary (BF-Diary) that includes patient-reported outcomes (PROs) associated with OIC...
  54. ncbi Prucalopride for constipation
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, College of Medicine, Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905, USA
    Expert Opin Pharmacother 11:451-61. 2010
    ..Chronic constipation has a high prevalence, and current medical and pharmacological therapies do not restore normal bowel function in all patients...
  55. doi Perspective: Conflict of interest and professional organizations: considerations and recommendations
    Michael Camilleri
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Acad Med 85:85-91. 2010
    ..The perspectives offered are intended to encourage individuals and learned bodies to further study and provide commentary and recommendations on managing COIs of a professional organization...
  56. pmc Review article: new receptor targets for medical therapy in irritable bowel syndrome
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 31:35-46. 2010
    ....
  57. doi Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study
    M Camilleri
    Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 21:1256-e117. 2009
    ..Prucalopride up to 2 mg once daily for 4 weeks was safe and well-tolerated by constipated elderly patients, with no differences vs placebo in ECG or a range of Holter-monitoring parameters...
  58. pmc LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 23:193-200. 2011
    ....
  59. pmc Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Biostatistics, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 138:98-107.e4. 2010
    ..We aimed to determine whether NPS induces expression of GI neuropeptides; and to associate NPSR1 single nucleotide polymorphisms (SNPs) with symptom phenotype and GI functions in health and functional GI disorders (FGID)...
  60. pmc Current and novel therapeutic options for irritable bowel syndrome management
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Charlton 8 110, 200 First St SW, Rochester, MN 55905, United States
    Dig Liver Dis 41:854-62. 2009
    ..The mechanisms and current evidence regarding efficacy of these agents are reviewed...
  61. pmc Genetics and irritable bowel syndrome: from genomics to intermediate phenotype and pharmacogenetics
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Dig Dis Sci 54:2318-24. 2009
    ..The aim of this study was to review the evidence of genetics in IBS based on genetic epidemiology, studies of association with intermediate phenotypes and pharmacogenetics...
  62. pmc Proximal and overall gastric emptying of solids in patients with reduced gastric volume accommodation compared to matched controls
    Michael Camilleri
    Mayo Clinic College of Medicine, Charlton 8 110, 200 First Street SW, Rochester, MN 55905, USA
    Dig Dis Sci 56:1729-34. 2011
    ..The effect of non-surgical impairment of gastric accommodation on gastric emptying is unclear. Non-surgical impairment of gastric accommodation is associated with accelerated gastric emptying...
  63. doi Opioid-induced constipation: challenges and therapeutic opportunities
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 106:835-42; quiz 843. 2011
    ..Novel patient response outcomes have been developed to facilitate demonstration of efficacy and safety of drugs in development for OIC...
  64. doi Enteric neurodegeneration in ageing
    M Camilleri
    Department of Medicine and Physiology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 20:418-29. 2008
    ..There is evidence that 5-HT(2) and 5-HT(4) mechanisms are involved in development, maintenance and survival of enteric neurons. Further research is needed to understand and potentially reverse enteric neurodegeneration...
  65. ncbi Managing conflict of interest in clinical practice
    Michael Camilleri
    Conflict of Interest Review Board and Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:607-14. 2007
    ..Conflict of interest is of concern because it compromises the trust of the patient and of society in the individual physician or the medical center...
  66. ncbi Clinical practice. Diabetic gastroparesis
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiologic Research, Mayo Clinic College of Medicine, Rochester, MN, USA
    N Engl J Med 356:820-9. 2007
  67. ncbi Drugs targeting functional bowel disorders: lessons from drug trials
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Curr Opin Pharmacol 2:684-90. 2002
    ....
  68. ncbi Diagnosis and treatment of enteric neuromuscular diseases
    Michael Camilleri
    Mayo Clinic, Charlton 8 110, 200 First St S W, Rochester, MN 55905, USA
    Clin Auton Res 13:10-5. 2003
    ....
  69. ncbi Is there a role for probiotics in irritable bowel syndrome?
    Michael Camilleri
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dig Liver Dis 38:S266-9. 2006
    ..These experimental and clinical observations suggest that probiotics may play a role in the management of IBS...
  70. pmc Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R Group and Gastroenterology Research Unit, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 132:17-25. 2007
    ..We explored the hypothesis that expression of these 2 proteins in colonic and rectal mucosa is abnormal in patients with IBS as compared with healthy controls...
  71. ncbi Review article: clinical evidence to support current therapies of irritable bowel syndrome
    M Camilleri
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Aliment Pharmacol Ther 13:48-53. 1999
    ..In summary, current therapies targeted on the predominant symptoms in IBS are moderately successful. New therapies are needed to more effectively relieve this syndrome, not just symptoms...
  72. ncbi Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans
    M Camilleri
    Department of Health Sciences Research, Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 19:30-8. 2007
    ..056) with the 10 and 20 mg t.i.d. doses. No safety issues were identified. ATI-7505 accelerates overall colonic transit and tends to accelerate GE and AC emptying and loosen stool consistency...
  73. ncbi A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 1:111-21. 2003
    ....
  74. ncbi Management of patients with chronic abdominal pain in clinical practice
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 18:499-506. 2006
    ....
  75. pmc Does delayed gastric emptying really cause symptoms in functional dyspepsia?
    M Camilleri
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gut 55:909-10. 2006
  76. ncbi GI clinical research 2002-2003: the year in review
    Michael Camilleri
    Mayo Clinic, Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 1:415-20. 2003
  77. ncbi Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders
    Michael Camilleri
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 130:1421-34. 2006
    ..It is anticipated that the interaction between investigators of basic science, basic and applied pharmacology, and clinical trials will lead to better treatment of these disorders...
  78. ncbi Objectives of the meeting: think opiates
    M Camilleri
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 16:1-2. 2004
  79. ncbi Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic, Charlton 8 110, 200 First Street SW, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 290:G942-7. 2006
    ..Thus the ClC-2 activator lubiprostone accelerates small intestinal and colonic transit, which confers potential in the treatment of constipation...
  80. ncbi Effect of renzapride on transit in constipation-predominant irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R Program, Gastroenterology Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 2:895-904. 2004
    ....
  81. ncbi Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome
    M Camilleri
    Mayo Clinic, Rochesster, MN 55905, USA
    Aliment Pharmacol Ther 16:1407-30. 2002
    ..Patient and physician education, early identification of psychosocial issues and better therapies are important strategies to reduce the suffering and societal cost of irritable bowel syndrome...
  82. ncbi Conflicts of interest and disclosures in publications
    Michael Camilleri
    Mayo Clinic, Charlton 8 110, 200 First Street SW, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 5:268-73. 2007
  83. ncbi Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 123:425-32. 2002
    ..Our hypothesis is that polymorphisms of the promoter region for the SERT influence colonic transit in response to treatment with alosetron in D-IBS...
  84. ncbi Clinical subgroups of chronic constipation: exploring the potential of polyethylene glycol
    M Camilleri
    Mayo Clinic, Rochester, MN, USA
    Ital J Gastroenterol Hepatol 31:S253-4. 1999
    ..However, first-line therapies such as dietary fibre and bulking agents should be tried initially prior to resorting to osmotic agents such as polyethylene glycol electrolyte solutions...
  85. doi Enteric neurodegeneration in ageing
    M Camilleri
    Departments of Medicine and Physiology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 20:185-96. 2008
    ..There is evidence that 5-HT(2) and 5-HT(4) mechanisms are involved in development, maintenance and survival of enteric neurons. Further research is needed to understand and potentially reverse enteric neurodegeneration...
  86. ncbi Pharmacology and clinical experience with alosetron
    M Camilleri
    Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Expert Opin Investig Drugs 9:147-59. 2000
    ..It also improves quality of life, has a high degree of tolerability and has an excellent safety profile to date...
  87. ncbi Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation
    Michael Camilleri
    Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 294:G13-9. 2008
    ....
  88. ncbi Functional dyspepsia: mechanisms of symptom generation and appropriate management of patients
    Michael Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic College of Medicine, Charlton 8 110, 200 First Street, SW, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 36:649-64, xi-x. 2007
    ..To achieve greater therapeutic efficacy, it may be necessary to target the therapeutic approach to a specific pathophysiology, such as impaired gastric emptying...
  89. pmc alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?
    Michael Camilleri
    Mayo Clinic, Charlton 8 110, 200 First St SW, Rochester, MN 55905, USA
    Gut 56:1337-8. 2007
  90. ncbi Functional bowel disease: roles of sensation and motility
    M Camilleri
    Gastroenterology Research Unit, Mayo Clinic, Charlton 7 154 200 First St S W, Rochester, MN 55905, USA
    Schweiz Med Wochenschr 130:1772-81. 2000
    ..Serotonergic and adrenergic agents are among the novel approaches that may have a significant impact on these disorders...
  91. pmc Serotonergic modulation of visceral sensation: lower gut
    M Camilleri
    Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Gut 51:i81-6. 2002
    ..They offer promise for the development of novel therapies for the treatment and control of irritable bowel syndrome...
  92. ncbi Review article: tegaserod
    M Camilleri
    Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 15:277-89. 2001
    ..Tegaserod was well-tolerated; the most frequent adverse event was transient diarrhoea...
  93. ncbi Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications
    M Camilleri
    CENTER Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 19:40-5. 2007
    ....
  94. ncbi Intestinal permeability and irritable bowel syndrome
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 19:545-52. 2007
    ....
  95. ncbi Enteric nervous system disorders: genetic and molecular insights for the neurogastroenterologist
    M Camilleri
    Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Neurogastroenterol Motil 13:277-95. 2001
    ....
  96. pmc Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls
    M Camilleri
    Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Gut 51:i34-40. 2002
    ..The principles and techniques involved in testing the hypothesis that visceral sensitivity is important are discussed, together with the controversies in the assumptions, methods, and interpretations of the data acquired to date...
  97. ncbi Appetite and obesity: a gastroenterologist's perspective
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER Group, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurogastroenterol Motil 19:333-41. 2007
    ....
  98. ncbi Alvimopan, a selective peripherally acting mu-opioid antagonist
    M Camilleri
    Clinical Enteric Neuroscience Translational and Epidemiological Research CENTER Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Neurogastroenterol Motil 17:157-65. 2005
    ..This review addresses the basic and applied pharmacology and current evidence for the use of the medication, alvimopan, in clinical gastroenterology...
  99. doi American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice
    M Camilleri
    CENTER Program, Mayo Clinic, Rochester, MN 55905, USA
    Neurogastroenterol Motil 20:1269-82. 2008
    ..Thus, intraluminal pressure measurements may contribute to the management of patients with disorders of gastrointestinal and colonic motility...
  100. pmc Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls
    Archana S Rao
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Biomedical Statistics and Informatics, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Physiol Gastrointest Liver Physiol 301:G919-28. 2011
    ..Urine sugars at 0-2 h and 8-24 h reflect SB and colonic permeability, respectively. IBS-D is associated with increased SB and colonic mucosal permeability...
  101. ncbi Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine
    Maria I Vazquez Roque
    Clinical Enteric Neuroscience Translational and Epidemiological Research Group, Gastroenterology Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 5:829-37. 2007
    ....

Research Grants17

  1. ALPHA 2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 1999
    ....
  2. Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions
    MICHAEL L CAMILLERI; Fiscal Year: 2010
    ..These actions may be relevant to develop new treatments for IBS. The studies will also provide further understanding of the potential of medications like medical marijuana on stomach function that may be relevant to appetite control. ..
  3. Pharmacogenomics of Gastric Function & Weight in Obesity
    Michael Camilleri; Fiscal Year: 2008
    ..It will also identifvphvsiological and genetic .factors that predict therapeutic success in the treatment of obesity with sibutramine. ..
  4. ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME
    Michael Camilleri; Fiscal Year: 2008
    ..Significance: This project will characterize pharmacogenetic mechanisms determining the response to clonidine through studies of candidate genes that control alpha2-adrenoreceptor function and norepinephrine transport in IBS. ..
  5. Pharmacogenomics of Gastric Function & Weight in Obesity
    Michael Camilleri; Fiscal Year: 2007
    ..It will also identify physiological and genetic factors that predict therapeutic success in the treatment of obesity with sibutramine. ..
  6. ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2007
    ..abstract_text> ..
  7. ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME
    Michael Camilleri; Fiscal Year: 2007
    ..Significance: This project will characterize pharmacogenetic mechanisms determining the response to clonidine through studies of candidate genes that control alpha2-adrenoreceptor function and norepinephrine transport in IBS. ..
  8. Pharmacogenomics of Gastric Function & Weight in Obesity
    MICHAEL L CAMILLERI; Fiscal Year: 2010
    ....
  9. ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2006
    ..abstract_text> ..
  10. Pharmacogenomics of Gastric Function & Weight in Obesity
    Michael Camilleri; Fiscal Year: 2005
    ..It will also identify physiological and genetic factors that predict therapeutic success in the treatment of obesity with sibutramine. ..
  11. ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2005
    ..abstract_text> ..
  12. ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2004
    ..abstract_text> ..
  13. ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2003
    ..abstract_text> ..
  14. ALPHA 2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2001
    ....
  15. ALPHA 2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2000
    ....
  16. Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions
    Michael Camilleri; Fiscal Year: 2009
    ..These actions may be relevant to develop new treatments for IBS. The studies will also provide further understanding of the potential of medications like medical marijuana on stomach function that may be relevant to appetite control. ..
  17. Pharmacogenomics of Gastric Function & Weight in Obesity
    Michael Camilleri; Fiscal Year: 2006
    ..It will also identify physiological and genetic factors that predict therapeutic success in the treatment of obesity with sibutramine. ..